Sara Patry, MD
Internal Medicine · Hutchinson, KSNPI 1679955363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$892
- AbbVie$822
- Amgen$800
- Pfizer$515
- Lilly USA, LLC$406
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,248100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $892 |
| AbbVie | 85 | $822 |
| Amgen | 59 | $800 |
| Pfizer | 50 | $515 |
| Lilly USA, LLC | 42 | $406 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $254 |
| Novartis | 9 | $135 |
| Sumitomo Pharma America, Inc. | 8 | $117 |
| Bayer | 8 | $109 |
| Daiichi Sankyo Inc. | 5 | $96 |
| Xeris Pharmaceuticals, Inc. | 4 | $88 |
| Nestle Healthcare Nutrition Inc. | 4 | $85 |
| Merck | 5 | $81 |
| Abbott | 5 | $77 |
| Abiomed | 3 | $74 |
| Boehringer Ingelheim | 4 | $70 |
| Exact Sciences | 4 | $60 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 3 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Corium, LLC | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| AstraZeneca | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| GSK | 2 | $28 |
| Johnson & Johnson | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $23 |
| Insulet Corporation | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Strongbridge US Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $13 |
How this compares
$5,248 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $101,760 |
| XareltoRivaroxaban | 124 | $85,616 |
| EliquisApixaban | 136 | $81,617 |
| JardianceEmpagliflozin | 56 | $45,157 |
| TrulicityDulaglutide | 30 | $38,112 |
| MyrbetriqMirabegron | 54 | $31,903 |
| GemtesaVibegron | 32 | $24,285 |
| MounjaroTirzepatide | 21 | $22,744 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $22,057 |
| JanuviaSitagliptin Phosphate | 20 | $19,164 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,356 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $16,678 |
| LinzessLinaclotide | 23 | $13,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,332 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $11,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $892 | $101,76077 claims |
| Johnson & JohnsonXarelto | $26 | $85,616124 claims |
| PfizerEliquis | $515 | $81,617136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $406 | $60,85651 claims |
| Boehringer IngelheimJardiance | $70 | $45,15756 claims |
| MerckJanuvia, Janumet | $81 | $35,84241 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $31,90354 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $24,28532 claims |
| AbbVieLinzess, Namzaric, Synthroid | $822 | $22,048100 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $28 | $21,28541 claims |
| AstraZenecaFarxiga, Symbicort | $32 | $17,67140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Hutchinson
- Mark YackleyHutchinson$10K
- Michael GreenHutchinson$7K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.